Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.54 +1.6%	$2.71	$2.07 ▼ $4.20	$81.78M	0.43	89,483 shs	23,656 shs
KYTX Kyverna Therapeutics	$2.55 -1.2%	$2.13	$1.78 ▼ $16.64	$110.21M	2.17	423,263 shs	295,718 shs
PVOTF BetterLife Pharma		$0.00	$0.03 ▼ $0.38	$21.70M	N/A	52,703 shs	198,200 shs
TCRX TScan Therapeutics	$1.45 +1.4%	$1.38	$1.02 ▼ $9.29	$82.06M	1.06	403,479 shs	369,502 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	-4.21%	-9.42%	-18.03%	+3.31%
KYTX Kyverna Therapeutics	+13.66%	+7.95%	+22.86%	-8.77%	-80.15%
PVOTF BetterLife Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
TCRX TScan Therapeutics	+3.62%	+18.18%	-10.63%	-25.13%	-83.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.1088 of 5 stars	3.6	3.0	0.0	0.0	2.2	1.7	0.0
KYTX Kyverna Therapeutics	2.1646 of 5 stars	3.6	3.0	0.0	0.0	2.5	1.7	0.0
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	4.0672 of 5 stars	4.5	4.0	0.0	0.0	3.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	254.33% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	625.49% Upside
PVOTF BetterLife Pharma	0.00	N/A	N/A	N/A
TCRX TScan Therapeutics	3.00	Buy	$7.80	437.93% Upside

Current Analyst Ratings Breakdown

Latest PVOTF, ANIX, TCRX, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
4/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00
3/26/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/25/2025	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/21/2025	ANIX Anixa Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/14/2025	TCRX TScan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$10.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	389.43	N/A	N/A	$0.59 per share	4.31
KYTX Kyverna Therapeutics	$7.03M	15.68	N/A	N/A	N/A	∞
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	$0.01 per share	N/A
TCRX TScan Therapeutics	$4.42M	18.56	N/A	N/A	$3.15 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.39	N/A	∞	N/A	N/A	-58.55%	-53.29%	6/3/2025 (Estimated)
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
PVOTF BetterLife Pharma	-$14.78M	N/A	N/A	N/A	N/A	N/A	-205.15%	-147.23%	N/A
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)

Latest PVOTF, ANIX, TCRX, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A
3/11/2025	Q1 2025	ANIX Anixa Biosciences	-$0.10	-$0.10	N/A	-$0.10	N/A	N/A
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.54	8.54
KYTX Kyverna Therapeutics	N/A	10.50	10.50
PVOTF BetterLife Pharma	N/A	3.62	3.62
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
KYTX Kyverna Therapeutics	18.08%
PVOTF BetterLife Pharma	N/A
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
KYTX Kyverna Therapeutics	22.00%
PVOTF BetterLife Pharma	34.77%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.20 million	24.05 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
PVOTF BetterLife Pharma	N/A	171.41 million	N/A	Not Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

PVOTF, ANIX, TCRX, and KYTX Headlines

Recent News About These Companies

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28 at 7:00 AM | globenewswire.com

TScan Therapeutics (NASDAQ:TCRX) & Relay Therapeutics (NASDAQ:RLAY) Head to Head Contrast

May 25 at 1:13 AM | americanbankingnews.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

Head-To-Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Twist Bioscience (NASDAQ:TWST)

May 22, 2025 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

May 14, 2025 | marketbeat.com

Equities Analysts Set Expectations for TCRX Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Equities Analysts Cut Earnings Estimates for TCRX

May 11, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TCRX Q1 Earnings

May 10, 2025 | marketbeat.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10, 2025 | nasdaq.com

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

May 9, 2025 | marketbeat.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

May 8, 2025 | marketbeat.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

May 7, 2025 | marketbeat.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

Adage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

April 30, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVOTF, ANIX, TCRX, and KYTX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.54 +0.04 (+1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 +0.00 (+0.20%)

As of 07:51 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Kyverna Therapeutics NASDAQ:KYTX

$2.55 -0.03 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 +0.01 (+0.20%)

As of 07:30 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

BetterLife Pharma OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

TScan Therapeutics NASDAQ:TCRX

$1.45 +0.02 (+1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$1.43 -0.02 (-1.38%)

As of 07:58 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time